Rebif Rebidose Approved for Multiple Sclerosis

Share this article:
REBIF REBIDOSE (interferon beta-1a) 8.8mcg/0.2mL, 22mcg/0.5mL, 44mcg/0.5mL inj by EMD Serono, Pfizer
REBIF REBIDOSE (interferon beta-1a) 8.8mcg/0.2mL, 22mcg/0.5mL, 44mcg/0.5mL inj by EMD Serono, Pfizer

EMD Serono and Pfizer announced that the FDA has approved Rebif Rebidose (interferon beta-1a), a single-use auto-injector for the self-administration of Rebif, a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS). Interferons possess immunomodulatory, antiviral, and antiproliferative biological activities.

Rebif Rebidose was evaluated in a 12-week Phase 3b multicenter, open-label, single-arm study (n=109) for the self-administration of Rebif with respect to ease of use, patient satisfaction and acceptability, and functional reliability.  Study results showed that the majority of patients found the device easy to use.

Rebif Rebidose will be available as a monthly pack in 22mcg and 44mcg doses, and as a titration pack. Rebif Rebidose is expected to be available early 2013.

For more information call (877) 447-3243 or visit www.Rebif.com.

Share this article:

Related Resources